艾力斯(688578.SH)擬以募集資金向江蘇艾力斯借款以實施募投項目
格隆匯12月29日丨艾力斯(688578.SH)公佈,根據公司《首次公開發行股票並在科創板上市招股説明書》,公司募集資金投資項目中“藥物研究分析檢測中心項目”的實施主體為公司全資子公司江蘇艾力斯生物醫藥有限公司(以下簡稱“江蘇艾力斯”)。為保障募投項目的順利實施,公司計劃將在中國銀行股份有限公司啟東支行開立的募集資金專户中的募集資金8666.94萬元及相應利息向全資子公司江蘇艾力斯提供借款,借款期限為自實際借款之日起不超過30個月,借款利率為市場基準同期貸款利率。根據募集資金投資項目建設實際需要,到期後可續借或提前償還。本次借款僅限用於“藥物研究分析檢測中心項目”的實施,不得用作其他用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.